Li et al. found IMP3 positivity in more than 50% of tumor cells in 93% of 42 serous carcinomas, and in only 7% of 8 endometrioid carcinomas and concluded that IMP3 may serve as a helpful biomarker in the distinction between these two tumor types (p <  0.001) [22]. Here, IMP3 is linked to endometrioid adenocarcinoma.